IL21 and diffuse large B-cell lymphoma: Interestingly, the effects of IL-21 in EBV+-DLBCL are not observed in EBV-negative DLBCL, suggesting a role for EBV lytic genes/products as contributors to the TME while highlighting the need of using distinct therapeutic approaches for the treatment of EBV-positive versus EBV-negative DLBCL.